CN1324040C - 治疗糖尿病及糖尿病并发症的药物、制备方法及其新用途 - Google Patents
治疗糖尿病及糖尿病并发症的药物、制备方法及其新用途 Download PDFInfo
- Publication number
- CN1324040C CN1324040C CNB2003101129280A CN200310112928A CN1324040C CN 1324040 C CN1324040 C CN 1324040C CN B2003101129280 A CNB2003101129280 A CN B2003101129280A CN 200310112928 A CN200310112928 A CN 200310112928A CN 1324040 C CN1324040 C CN 1324040C
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma fagopyri
- fagopyri tatarici
- rat
- myelin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 208000002249 Diabetes Complications Diseases 0.000 title description 11
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 235000011949 flavones Nutrition 0.000 claims description 140
- 229930003944 flavone Natural products 0.000 claims description 136
- 150000002213 flavones Chemical class 0.000 claims description 63
- 210000003497 sciatic nerve Anatomy 0.000 claims description 31
- 230000007830 nerve conduction Effects 0.000 claims description 13
- 230000009467 reduction Effects 0.000 claims description 5
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 23
- 244000130270 Fagopyrum tataricum Species 0.000 abstract description 20
- 235000014693 Fagopyrum tataricum Nutrition 0.000 abstract description 19
- 230000008569 process Effects 0.000 abstract description 5
- 238000007670 refining Methods 0.000 abstract description 4
- 229930003935 flavonoid Natural products 0.000 abstract description 3
- 150000002215 flavonoids Chemical class 0.000 abstract description 3
- 235000017173 flavonoids Nutrition 0.000 abstract description 3
- 244000025254 Cannabis sativa Species 0.000 abstract 2
- 230000000225 effect on diabetes Effects 0.000 abstract 1
- 235000013402 health food Nutrition 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 115
- 210000005012 myelin Anatomy 0.000 description 96
- 102000006386 Myelin Proteins Human genes 0.000 description 94
- 108010083674 Myelin Proteins Proteins 0.000 description 94
- 239000002775 capsule Substances 0.000 description 82
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 74
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 73
- 150000002212 flavone derivatives Chemical class 0.000 description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- 210000003050 axon Anatomy 0.000 description 42
- 239000000243 solution Substances 0.000 description 34
- 210000004126 nerve fiber Anatomy 0.000 description 33
- 230000008961 swelling Effects 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 238000003756 stirring Methods 0.000 description 28
- 238000001035 drying Methods 0.000 description 26
- 230000001537 neural effect Effects 0.000 description 25
- 210000002700 urine Anatomy 0.000 description 24
- 210000004204 blood vessel Anatomy 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 239000012043 crude product Substances 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 14
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 230000017531 blood circulation Effects 0.000 description 13
- 238000002156 mixing Methods 0.000 description 13
- 238000004043 dyeing Methods 0.000 description 12
- 235000012054 meals Nutrition 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 11
- 210000000416 exudates and transudate Anatomy 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 231100000915 pathological change Toxicity 0.000 description 11
- 230000036285 pathological change Effects 0.000 description 11
- 238000011552 rat model Methods 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 102000001554 Hemoglobins Human genes 0.000 description 10
- 108010054147 Hemoglobins Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 210000003161 choroid Anatomy 0.000 description 10
- 230000001788 irregular Effects 0.000 description 10
- 238000000967 suction filtration Methods 0.000 description 10
- 210000002469 basement membrane Anatomy 0.000 description 9
- -1 chromocor compound Chemical class 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000004040 coloring Methods 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000012670 alkaline solution Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 229960003180 glutathione Drugs 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- 210000004116 schwann cell Anatomy 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 206010003694 Atrophy Diseases 0.000 description 5
- 206010012655 Diabetic complications Diseases 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 241000209140 Triticum Species 0.000 description 5
- 235000021307 Triticum Nutrition 0.000 description 5
- 230000037444 atrophy Effects 0.000 description 5
- 210000000721 basilar membrane Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000001434 glomerular Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 210000000713 mesentery Anatomy 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 210000005239 tubule Anatomy 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 206010053648 Vascular occlusion Diseases 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 238000005057 refrigeration Methods 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 208000021331 vascular occlusion disease Diseases 0.000 description 4
- DTGKSKDOIYIVQL-NQMVMOMDSA-N (+)-Borneol Natural products C1C[C@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-NQMVMOMDSA-N 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 3
- 208000002109 Argyria Diseases 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 240000005636 Dryobalanops aromatica Species 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 229960000846 camphor Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000008807 pathological lesion Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011122 softwood Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 2
- 102000016912 Aldehyde Reductase Human genes 0.000 description 2
- 108010053754 Aldehyde reductase Proteins 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 241000219051 Fagopyrum Species 0.000 description 2
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 2
- 102000002151 Microfilament Proteins Human genes 0.000 description 2
- 108010040897 Microfilament Proteins Proteins 0.000 description 2
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000166550 Strophanthus gratus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000000739 chaotic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 229930182486 flavonoid glycoside Natural products 0.000 description 2
- 150000007955 flavonoid glycosides Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000010956 nickel silver Substances 0.000 description 2
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 2
- 229960003343 ouabain Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 240000000491 Corchorus aestuans Species 0.000 description 1
- 235000011777 Corchorus aestuans Nutrition 0.000 description 1
- 235000010862 Corchorus capsularis Nutrition 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 241000872198 Serjania polyphylla Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- FOGVNFMUZXDMTR-UHFFFAOYSA-N [Mg].Cl Chemical compound [Mg].Cl FOGVNFMUZXDMTR-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- QGNBTYAQAPLTMX-UHFFFAOYSA-L calcium dobesilate Chemical compound [Ca+2].OC1=CC=C(O)C(S([O-])(=O)=O)=C1.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 QGNBTYAQAPLTMX-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000002239 ischium bone Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver nitrate Substances [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- LUBHDINQXIHVLS-UHFFFAOYSA-N tolrestat Chemical compound OC(=O)CN(C)C(=S)C1=CC=CC2=C(C(F)(F)F)C(OC)=CC=C21 LUBHDINQXIHVLS-UHFFFAOYSA-N 0.000 description 1
- 229960003069 tolrestat Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
芦丁浓度C(g/L) | 0.01203 | 0.02406 | 0.04811 | 0.07217 | 0.09622 |
吸光度A | 0.144 | 0.287 | 0.572 | 0.852 | 1.127 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101129280A CN1324040C (zh) | 2003-12-26 | 2003-12-26 | 治疗糖尿病及糖尿病并发症的药物、制备方法及其新用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101129280A CN1324040C (zh) | 2003-12-26 | 2003-12-26 | 治疗糖尿病及糖尿病并发症的药物、制备方法及其新用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1634953A CN1634953A (zh) | 2005-07-06 |
CN1324040C true CN1324040C (zh) | 2007-07-04 |
Family
ID=34843365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101129280A Expired - Lifetime CN1324040C (zh) | 2003-12-26 | 2003-12-26 | 治疗糖尿病及糖尿病并发症的药物、制备方法及其新用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1324040C (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101066299B (zh) * | 2007-06-13 | 2010-09-22 | 薛九荣 | 富含苦荞黄酮的苦荞提取物的提取方法及其产品 |
CN104069187B (zh) * | 2014-07-24 | 2016-06-01 | 劲牌生物医药有限公司 | 从苦荞麦中提取纯化苦荞黄酮的工艺方法 |
CN104855646A (zh) * | 2015-05-15 | 2015-08-26 | 吉林农业大学 | 荞麦壳茶 |
CN104825552A (zh) * | 2015-05-15 | 2015-08-12 | 吉林农业大学 | 一种荞麦壳黄酮提取物及其作为AGEs抑制剂的应用 |
CN105067814A (zh) * | 2015-07-24 | 2015-11-18 | 中国科学院成都生物研究所 | 解旋酶水解atp活性测定方法 |
CN107898829A (zh) * | 2017-09-26 | 2018-04-13 | 吉林农业大学 | 糖基化终末产物裂解剂 |
TWI794575B (zh) * | 2019-09-10 | 2023-03-01 | 大江生醫股份有限公司 | 化合物用於預防及/或治療高血脂症之用途 |
CN112717003A (zh) * | 2021-01-29 | 2021-04-30 | 温州大学 | 苦荞黄酮在制备治疗糖尿病诱导的组织损伤药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1410423A (zh) * | 2001-09-28 | 2003-04-16 | 张杰克 | 提取芦丁的工艺方法 |
-
2003
- 2003-12-26 CN CNB2003101129280A patent/CN1324040C/zh not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1410423A (zh) * | 2001-09-28 | 2003-04-16 | 张杰克 | 提取芦丁的工艺方法 |
Non-Patent Citations (6)
Title |
---|
从苦荞麦中提取芦丁的研究 杨德全等,延安大学学报 自然科学版,第16卷第4期 1997 * |
从苦荞麦中提取芦丁的研究 杨德全等,延安大学学报 自然科学版,第16卷第4期 1997;苦荞麦茎及籽壳中黄酮类化合物(芦丁)的提取及其鉴定 贾冬英等,食品科学,第19卷第9期 1998;冷碱法从槐米中提取芦丁的试验研究 战玉琴等,中成药,第7期 1994;实验性糖尿病大鼠周围神经病变的研究 张蜀平,西南国防医药,第8卷第2期 1998;糖尿病神经病变的治疗现状 徐琪,医学综述,第7卷第9期 2001 * |
冷碱法从槐米中提取芦丁的试验研究 战玉琴等,中成药,第7期 1994 * |
实验性糖尿病大鼠周围神经病变的研究 张蜀平,西南国防医药,第8卷第2期 1998 * |
糖尿病神经病变的治疗现状 徐琪,医学综述,第7卷第9期 2001 * |
苦荞麦茎及籽壳中黄酮类化合物(芦丁)的提取及其鉴定 贾冬英等,食品科学,第19卷第9期 1998 * |
Also Published As
Publication number | Publication date |
---|---|
CN1634953A (zh) | 2005-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101961059B (zh) | 一种普洱茶提取物及制备方法和应用 | |
CN101612312A (zh) | 一种中药组合物在制备治疗糖尿病并发症药物中的应用 | |
CN101961060A (zh) | 一种普洱茶提取物及制备方法和应用 | |
CN101961061A (zh) | 一种普洱茶提取物及制备方法和应用 | |
CN1324040C (zh) | 治疗糖尿病及糖尿病并发症的药物、制备方法及其新用途 | |
CN110201067A (zh) | 一种藤茶提取物及其制备方法和应用 | |
CN109553599A (zh) | 一种蓝莓花青素及其制备方法和应用 | |
CN104491048B (zh) | 一种枇杷叶总倍半萜苷提取物及其制备方法与应用 | |
CN107041924A (zh) | 一种防治糖尿病肾病的朝药复方提取物及其制备方法 | |
CN102716135A (zh) | 羽扇豆酮在制备预防或治疗糖尿病的产品中的应用 | |
CN102552299A (zh) | 薯蓣皂苷在制备预防及治疗糖尿病药物中的应用 | |
CN115645473A (zh) | 竹叶兰及其提取物在制备治疗肾损伤药物中的应用 | |
CN105560308B (zh) | 金花葵花在制备用于预防和治疗前列腺疾病的产品中的应用 | |
CN1268319C (zh) | 一种圣地红景天注射液制剂及其制备方法 | |
CN107441107A (zh) | 一种具有清热、解毒、消炎作用的中药组合物及其制备方法 | |
CN103393928B (zh) | 大容量生脉注射液及其制备方法 | |
CN101181333B (zh) | 治疗心脑血管疾病的中药注射剂及其制法和检测方法 | |
CN102846715A (zh) | 一种治疗糖尿病合并高脂蛋白血症的药物及其制作方法 | |
CN101979084B (zh) | 一种温肾补阳中药组合物及其制备方法 | |
CN1274339C (zh) | 氨杞制剂及其制备方法和用途 | |
CN101190254B (zh) | 葛根或其提取物与瓜蒌或其提取物的药物组合物 | |
CN1047310C (zh) | 一种治疗颅内压升高症的注射液 | |
CN102626438B (zh) | 一种抗糖尿病药物及制备方法 | |
CN110090274A (zh) | 一种治疗鸡肾肿湿热症的中药组合物及制备方法和应用 | |
CN106608899B (zh) | 20(r)-原人参三醇及衍生物的制备方法和医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANXI YABAO PHARMACEUTICAL GROUP CORP. Free format text: FORMER OWNER: SHANXI FENGLINGDU DEVELOPMENT ZONE ZHONGLI INVESTMENT DEVELOPMENT CO., LTD. Effective date: 20130628 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 044600 YUNCHENG, SHAANXI PROVINCE TO: 044602 YUNCHENG, SHAANXI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130628 Address after: 044602 Shanxi city of Yuncheng province Fenglingdu Economic Development Zone No. 1 Industrial Avenue Patentee after: SHANXI YABAO PHARMACEUTICAL Group Corp. Address before: 044600 Shanxi province Fenglingdu Economic Development Zone No. 1 Industrial Avenue Patentee before: Shanxi Fenglingdu Development Zone Zhongli Investment Development Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20070704 |